ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2016
Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Pooled it
- Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review.Pain research & management · 2022Pooled it
- High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis.Journal of translational medicine · 2021Pooled it
- Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.Headache · 2019Trial
- Neurochemical Changes Following Botulinum Toxin Type A in Chronic Migraine: An LC-MS/MS and HPLC Evaluation of Plasma and Urinary Biomarkers.Journal of clinical medicine · 2026Article
- Non-Migraine Head Pain and Botulinum Toxin.Toxins · 2024Review
- The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session.Frontiers in neurology · 2024Article
- Article
- Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review.Life (Basel, Switzerland) · 2023Review
- Review
- Article
- Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety.Scientific reports · 2021Article
- Withdrawal failure in patients with chronic migraine and medication overuse headache.Acta neurologica Scandinavica · 2021Article
- OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy.Journal of clinical medicine · 2021Review
- The Use of Botulinum Toxin for Treatment of Depression.Handbook of experimental pharmacology · 2021Article
- Mapping Assessments Instruments for Headache Disorders against the ICF Biopsychosocial Model of Health and Disability.International journal of environmental research and public health · 2020Review
- The effect of greater occipital nerve blockade on the quality of life, disability and comorbid depression, anxiety, and sleep disturbance in patients with chronic migraine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Article
- Observational
- Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain.Regional anesthesia and pain medicine · 2019Article
- Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.The journal of headache and pain · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic migraine causes a serious labour loss and disability in the society and increases the risk of depression and anxiety by negatively affecting the quality of life. The purpose of this study was to investigate the effects of onabotulinumtoxinA (BoNT-A) treatment on efficacy before and after treatment in our cases with chronic migraine as well as on depression, anxiety and disability caused by migraine. According to the International Headache Classification (ICHD-III beta version), 60 adult patients who were diagnosed with chronic migraine were included in the study. A total of 155 IU BoNT-A treatment from 31 regions was administered in accordance with the protocol of PREEMPT study. Information about the characteristics of patients' headaches, background and family history, drugs they used was recorded. At the baseline and in the first and third month after the BoNT-A injection, VAS scores, the number of both headache days and attacks, the headache duration, the frequency of application to emergency services and the intake of both analgesics and triptans during attacks were evaluated. MIDAS, BDI and BAI were evaluated at the baseline and in the third month after the BoNT-A injection. BoNT-A injection provided a significant decrease in the number of days and severity of headaches, MIDAS disability scores and psychiatric complaints in cases with chronic migraine who did not respond to prophylactic treatments in the third month of the treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.